1. The progress of AAV-mediated gene therapy in neuromuscular disorders;Aguti;Expert Opin. Biol. Ther.,2018
2. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficiency and safety results from the phase 2 NURTURE study;De Vivo;Neuromuscul. Disord.,2019
3. Spinal muscular atrophy: mutations, testing, and clinical relevance;Keinath;Appl. Clin. Genet.,2021
4. Prior, T. W., Leach, M. E., Finanger, E., February 24, 2000. Spinal muscular atrophy. Adam, M.P., Everman, D.B. Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., (editors). In GeneReviews. University of Washington, Seattle (WA), 1993–2023 [updated December 3, 2020]. PMID 20301526.
5. Therapeutic approaches for spinal muscular atrophy (SMA);Scoto;Gene Ther.,2017